Muhammad Nadeem, MBBS, Caitlyn D Lesh, MD, Steven Schwaitzberg, MD, Alan Posner, MD. University at Buffalo
Introduction: Gastric bypass has been an acceptable treatment for the morbidly obese patient, with proven efficacy on weight loss and remission of co morbidities, especially diabetes (T2DM). Laparoscopic sleeve gastrectomy (LSG) is gaining momentum as an alternative procedure for the morbidly obese patient. The aim of this study is to assess the resolution of T2DM by examining HbA1c, BMI, fat %, and % excess weight loss in T2DM patients in our LSG patients.
Methods: We performed a retrospective chart review of 33 T2DM patients before and after LSG, analyzing HgA1c, BMI, % weight loss, fat %, and diabetic medications. Data was analyzed by using SPSS version 24. Paired T-test was applied to see the significance of BMI, weight, fat % and HbA1c before and after the procedure.
Results: One year following LSG mean BMI decreased significantly from 47.62 to 36.68 (p=<0.001, CI 9.04-12.83), mean body weight dropped from 132.94 lb to 103.53 lb (p=<0.001, CI 24.7-34.12), and fat % decreased from 48.93 % to 39.35% (p=<0.001, CI 6.62-12.74). HbA1c improved significantly from mean 7.15 to 6.20 (p=<0.004, CI 0.33-1.55). Oral diabetic medications and insulin requirement decreased from 75.8 % to 24.2% and 39.4% to 15.2 % respectively.
Conclusion: Laparoscopic sleeve gastrectomy is an acceptable treatment for the morbidly obese T2DM patient.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 88362
Program Number: P600
Presentation Session: iPoster Session (Non CME)
Presentation Type: Poster